FR3013221B1 - Composition pharmaceutique effervescente a base de sildenafil et son procede de fabrication - Google Patents

Composition pharmaceutique effervescente a base de sildenafil et son procede de fabrication Download PDF

Info

Publication number
FR3013221B1
FR3013221B1 FR1461212A FR1461212A FR3013221B1 FR 3013221 B1 FR3013221 B1 FR 3013221B1 FR 1461212 A FR1461212 A FR 1461212A FR 1461212 A FR1461212 A FR 1461212A FR 3013221 B1 FR3013221 B1 FR 3013221B1
Authority
FR
France
Prior art keywords
sildenafil
pharmaceutical composition
manufacturing process
composition based
effervescent pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1461212A
Other languages
English (en)
Other versions
FR3013221A1 (fr
Inventor
Nabil Said
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of FR3013221A1 publication Critical patent/FR3013221A1/fr
Application granted granted Critical
Publication of FR3013221B1 publication Critical patent/FR3013221B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a pour objet une composition pharmaceutique effervescente destinée à l'administration par voie orale d'un inhibiteur de la phosphodiestérase de type 5 (PDE5) : le sildénafil. Cette composition se caractérise par une action plus rapide (forme à libération accélérée), un goût agréable obtenu par masquage de l'amertume du principe actif, et facilité de l'administration, surtout pour les patients présentant des difficultés de déglutition.
FR1461212A 2013-11-19 2014-11-19 Composition pharmaceutique effervescente a base de sildenafil et son procede de fabrication Active FR3013221B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TN20130480 2013-11-19

Publications (2)

Publication Number Publication Date
FR3013221A1 FR3013221A1 (fr) 2015-05-22
FR3013221B1 true FR3013221B1 (fr) 2020-11-27

Family

ID=52392057

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1461212A Active FR3013221B1 (fr) 2013-11-19 2014-11-19 Composition pharmaceutique effervescente a base de sildenafil et son procede de fabrication

Country Status (1)

Country Link
FR (1) FR3013221B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
WO2002005820A1 (fr) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Dispersions solides de citrate de sildenafil ayant une forte solubilite dans l'eau
FR2823668B1 (fr) * 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles

Also Published As

Publication number Publication date
FR3013221A1 (fr) 2015-05-22

Similar Documents

Publication Publication Date Title
CL2017000669A1 (es) Forma de dosificación farmacéutica (divisional de la solicitud 1029/2014)
CL2017003445A1 (es) Formas solidas y formulaciones de compuestos de imidazopirazina.
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
MA44674A (fr) Inhibiteurs de bromodomaine
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
ECSP066826A (es) Inhibidores de integrasa de vih
ATE543489T1 (de) Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
EA201101432A1 (ru) Активный фармацевтический ингредиент, адсорбированный на твердой подложке
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
EP4249071A3 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
EA201490223A1 (ru) Составы на основе дарунавира
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
EA201990093A1 (ru) Двухкомпонентная композиция
ECSP21067104A (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
EA201990947A1 (ru) Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
FR3013221B1 (fr) Composition pharmaceutique effervescente a base de sildenafil et son procede de fabrication
EA202192118A1 (ru) Фармацевтическая композиция, содержащая ацетаминофен и ибупрофен

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 7

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10